Navigation Links
Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
Date:8/1/2011

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Highlights

• Provides detailed analysis of sustained release injectable products, market segments, market dynamics and market demographics

• Analyzes therapeutic demand drivers and evaluates commercial sustained release injectables in eleven major therapeutic segments

• Charts sustained release product data and market share, and provides forecasts to 2015

• Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliations

Executive Summary

Injectable Drug Market Dynamics

The Trend toward Self-Administration

Shifting Demographics

Injectable Drug Formulation Technology

Innovation in Injectable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

Sustained Release Injectables - Branded Formulation Technologies

Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

Other Polymers

ChroniJect

CriticalMix

Depofoam

LinkeRx

Liposomes

Medisorb

Medusa

Optisomes

OxtoDEX

SABER/SAIB

Sucrose acetate isobutyrate

SynBiosys

Supercritical Fluid

Analysis of FDA Approved Sustained Release Injectables

cytarabine

goserelin acetate

Interferon

lanreotide acetate

leuprolide acetate

morphine

naltrexone

olanzapine

octreotide acetate

risperidone

paliperidone palmitate

somatostatin

triptorelin pamoate

Development-Stage SR Injectable Drug Candidate Assessment

Addiction

Antivirals

Hormones

Immune Modulators

Incretin Mimetics

Local Anesthetics

Opioid Antagonists

Psychotropics

Antineoplastics

SR Injectables – Therapeutic Sector Impact Analysis & Forecasts

Addiction

Autoimmune Diseases

Diabetes

Infectious Disease

Macular Degeneration

Metabolic Diseases

Neurology

Oncology

Pain Management

Reproductive Health

Sustained Release Injectables – Company Profiles

To order this report:

Drug and Medication Industry: Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- According to a new market research ... Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, 8mm, ... Purchase (Retail, Non-Retail) - Trends & Global Forecasts to ... for the forecast period of 2016 to 2021. This ... 2021 from USD 1.65 Billion in 2016, growing at ...
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... payment industry today announced its strategic partnership with Connance, a healthcare industry ... The two companies’ proven, proprietary technology combine to provide health systems, hospitals ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
Breaking Medicine News(10 mins):